- 24/7 Wall St.•5 months ago
Nymox Pharmaceutical shares jumped following the announcement of positive results from its late-stage prostate cancer trial.
- TheStreet.com•7 months ago
Nymox will not be successful in convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.
NYMX : Summary for Nymox Pharmaceutical Corporatio - Yahoo Finance
Nymox Pharmaceutical Corporation (NYMX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Ask||4.00 x 800|
|Day's Range||3.18 - 3.25|
|52 Week Range||1.62 - 5.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-9.61|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|